Cargando…
ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma
Low-risk gestational trophoblastic neoplasia including choriocarcinoma is often effectively treated with Methotrexate (MTX) as a first line therapy. However, MTX resistance (MTX-R) occurs in at least ≈33% of cases. This can sometimes be salvaged with actinomycin-D but often requires more toxic combi...
Autores principales: | Georgiou, Marina, Ntavelou, Panagiota, Stokes, William, Roy, Rajat, Maher, Geoffrey J., Stoilova, Tsvetana, Choo, Josephine A.M.Y., Rakhit, Callum P., Martins, Miguel, Ajuh, Paul, Horowitz, Neil, Berkowitz, Ross S., Elias, Kevin, Seckl, Michael J., Pardo, Olivier E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054653/ https://www.ncbi.nlm.nih.gov/pubmed/35301407 http://dx.doi.org/10.1038/s41388-022-02251-8 |
Ejemplares similares
-
Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma
por: Georgiou, Marina, et al.
Publicado: (2022) -
Mechanism of Methotrexate‐sensitivity of Choriocarcinoma Cells in Culture
por: Indue, Takami, et al.
Publicado: (1988) -
AKR1C3 Overexpression Mediates Methotrexate Resistance in Choriocarcinoma Cells
por: Zhao, Jing, et al.
Publicado: (2014) -
Methotrexate induces DNA damage and inhibits homologous recombination repair in choriocarcinoma cells
por: Xie, Lisha, et al.
Publicado: (2016) -
SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells
por: Shi, Dazun, et al.
Publicado: (2020)